Prognostic and predictive factors for lung cancer

Paesmans, Marianne

doi:10.1183/20734735.006911

Cited by 48 publications

(47 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, reproducible and well-established independent prognostic factors are lacking [3]. Indeed, most often, identification of prognostic factors is performed retrospectively and there are few, if any, for patients with small cell lung Data are presented as hazard ratios (95% CI), unless otherwise stated.…”

Section: Discussionmentioning

confidence: 99%

“…The most reproducible prognostic factor is disease extent, which is also the main factor guiding therapy. Very few other prognostic factors have been clearly established: performance status, sex and some routine biological parameters, such neutrophil or leukocyte counts, or albuminaemia [2,3]. Our group, the European Lung Cancer Working Party (ELCWP), has long been interested in the identification of prognostic factors, and their integration in a classification system that could be used in care for providing information to patients and in clinical research for stratifying randomisation procedures or adjusting treatment comparisons.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Validation and comparison of several published prognostic systems for patients with small cell lung cancer

Paesmans

Lafitte²,

Lecomte³

et al. 2011

European Respiratory Journal

View full text Add to dashboard Cite

The aim of the present study was to validate and compare published prognostic classifications for predicting the survival of patients with small cell lung cancer.We pooled data from phase III randomised clinical trials, and used Cox models for validation purposes and concordance probability estimates for assessing predictive ability.We included 693 patients. All the classifications impacted significantly on survival, with hazard ratios (HRs) in the range 1.57-1.68 (all p,0.0001). Median survival times were 16-19 months for the best predicted groups, while they were 6-7 months for the most poorly predicted groups. Most of the paired comparisons were statistically significant. We obtained similar results when restricting the analysis to patients with extensive disease. Multivariate Cox models for fitting survival data were also performed. The HRs for a single covariate were 8.23 (95% CI 5.88-11.69), and 9.46 (6.67-13.50), and for extensive disease were 5.60 (3.13-9.93), 12.49 (5.57-28.01) and 8. 83 (4.66-16.64). Concordance probability estimates ranged 0.55-0.65 (overlapping confidence intervals).Published classifications were validated and suitable for use at a population level. As expected, prediction at an individual level remains problematic. A specific model designed for extensivedisease patients did not appear to perform better.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Validation and comparison of several published prognostic systems for patients with small cell lung cancer

Paesmans

Lafitte²,

Lecomte³

et al. 2011

European Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…In several studies, clinical and biological data like age [11], sex [9], histological typing, WHO PS score [16,17], TNM staging [12,18], weight (kg) [16], weight lost (% of usual weight) [16], blood hemoglobin (g/dl) [12], leukocytes (ϫ 10 9 /l) [11], platelets (ϫ 10 9 /l) [13], proteins (mg/l), albumin (mg/l) [19], calcium (mg/l) [12], and lactate dehydrogenase (LDH) (U/l) [12] were found to be prognostic factors in NSCLC. All these data were recorded.…”

Section: Data Collectedmentioning

confidence: 99%

How Accurate Are Physicians in the Prediction of Patient Survival in Advanced Lung Cancer?

et al. 2010

View full text Add to dashboard Cite

Background. Because most cases of non-small cell lung cancer (NSCLC) are diagnosed at an advanced stage with a poor prognosis, patient inclusion in clinical trials is critical. Most trials require an estimated life expectancy >3 months, based on clinician estimates of patient survival probability, without providing formal guidelines. The aim of this study was to assess the accuracy of clinicians' predictions of survival in NSCLC patients (stages IIIB, and IV) and the possible impact of patient quality of life on survival estimation.Methods. At diagnosis, clinical, biological, and quality of life data (QLQ-C30 questionnaire) were recorded, and doctors "forecast" each patient's estimated survival. Concordance between predicted and actual survival was assessed with the intraclass correlation coefficient.Results. Eighty-five patients with a mean age of 62.2 years, 81.1% male, were included (squamous cell carci-

show abstract

“…A prognostic factor is generally defi ned as a factor, measured before treatment, that has an impact on a patient's outcome "independently" of received treatment or of the general class of treatment (1). With the exception of stage and performance status, no prognostic factors have been defi nitively established in lung cancer (2).…”

Section: Introductionmentioning

confidence: 99%

Tumour metabolic activity measured by fluorodeoxyglucose positron emission tomography for radiotherapy planning as a prognostic factor for locally advanced non-small cell lung cancer

Masarykova¹,

Šćepanović²,

Povinec³

et al. 2018

BLL

View full text Add to dashboard Cite

OBJECTIVES: To analyse whether the maximum standardized uptake value of the positron emission tomography/computed tomography for radiotherapy planning was useful as a prognostic factor for tumour response and survival of patients with locally advanced non-small cell lung cancer. BACKGROUND: Increased 18F-fl uoro-2-deoxyglucose uptake by lung cancer cells, measured as the maximum standardized uptake value, has been reported to predict the biologic aggressiveness of both early and advanced non-small cell lung cancer. METHODS: A prospective study was performed in 61 consecutive patients with unresectable stage IA-IIIB of non-small cell lung cancer. The mean age was 65 years. Seventy fi ve percent of patients in the entire group received an induction chemotherapy. The mean dose of radiotherapy was 61Gy. All patients underwent 18F-fl uoro-2-deoxy-D-glucose positron emission tomography/computed tomography for radiotherapy planning. RESULTS: Thirty six percent of the patients experienced a complete response and 20 % had a partial tumour response. Forty four percent of the patients suffered from a progressive disease. The maximum standardized uptake value of the primary tumour more than 11.4 was correlated with a worse tumour response (p = 0.0001) and a shorter survival of our patients (p = 0.0109). CONCLUSION: We found a correlation between the maximum standardized uptake value and the patient prognosis and lung cancer aggressiveness (Tab. 3, Fig. 5, Ref. 18). Text in PDF www.elis.sk.

show abstract

Prognostic and predictive factors for lung cancer

Cited by 48 publications

References 63 publications

Validation and comparison of several published prognostic systems for patients with small cell lung cancer

Validation and comparison of several published prognostic systems for patients with small cell lung cancer

How Accurate Are Physicians in the Prediction of Patient Survival in Advanced Lung Cancer?

Tumour metabolic activity measured by fluorodeoxyglucose positron emission tomography for radiotherapy planning as a prognostic factor for locally advanced non-small cell lung cancer

Contact Info

Product

Resources

About